Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.

Publikation

Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.

Wissenschaftlicher Artikel/Review - 15.06.2023

Silzle Tobias, Kahlert Christian, Albrich Werner, Nigg Susanne, Demmer-Steingruber Ruth, Driessen Christoph, Fischer Stefanie

Zitation

Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. Swiss Med Wkly 2023; 153:40090.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Swiss Med Wkly 2023; 153

Veröffentlichungsdatum

15.06.2023

eISSN (Online)

1424-3997

Seiten

40090

Kurzbeschreibung/Zielsetzung

Currently available messenger ribonucleic acid (mRNA)-based vaccines against coronavirus disease (COVID-19) have been shown to be effective even in highly immunocompromised hosts, including patients with multiple myeloma. However, vaccination failure can be observed in all patient groups.